NeuroVision Inc. (RevitalVision)

www.neuro-vision.com

High-Tech Company

Acquired by RevitalVision

TECH VERTICALS

Artificial Intelligence, Computer Vision, Healthtech, Life Sciences, Machine Vision, Medical Devices, MedTech

General Data

Sector	Medical Devices
Company Stage:	Initial Revenues
Established	1999
Number of Employees	8
Reg. Number:	abCDe

DESCRIPTION

NeuroVision developed the Neural Vision Correction (NVC) - a non-invasive, patient-specific treatment treating and improving vision abilities. The technology was based on visual stimulation and facilitation of neural connections responsible for vision. The technology was clinically proven in the treatment of adult amblyopia ("lazy eye"); this treatment received FDA clearance. Additional proof-of-concept studies have been performed indicating the technology's potential to treat low myopia and presbyopia (loss of near vision with age). These studies have also demonstrated NVC as a means to deliver "super normal" vision to those with normal (20/20) vision. The company received Medical CE-Mark to market its Amblyopia and Low-Myopia products in the EU. NeuroVision's products were also approved for use in Israel by the Israeli Ministry of Health - Device License Authority.

TECHNOLOGY

NeuroVision has developed NVC™ vision correction technology based on breakthroughs in the field of visual neuroscience. The Company leverages known discoveries in adult neural plasticity and more specifically in our proprietary understanding of the neural connections responsible for vision.

Through NeuroVision's proprietary and systematic approach to improving neural processing in the visual cortex, visual function can be dramatically improved.

Improved visual function is achieved through repetitive performance of interactive Visual Perception Tasks, where subject-specific stimuli are administered on a treatment workstation.

NeuroVision's NVC™ vision correction technology is formed around its proprietary algorithms, which are delivered to treatment workstations via the Internet. These algorithms provide analysis of each subject's dysfunctions, resulting in an individualized treatment.

This non-invasive treatment plan is arranged in 30-min sessions, taken every other day. Maximal improvement is subject dependant, typically achieved in a course of 6-8 weeks.

NVC has been clinically proven in the treatment of adult amblyopia ("lazy eye"), a condition once considered untreatable, and more recently in providing low myopes (<1.5D) with 20/20 uncorrected vision.

Products and Phases

Product	Phase
NeuroVision(TM)	FDA Approved CE Approved
Patented computerized visual tasks that can improve eyesight.

	TARGET MARKETS
	Patients with problems in their vision abilities.

	BUSINESS MODEL
	B2C

REMARKS

Date	Remark
01/01/2009	the company's IP was acquired by RevitalVision LLC (a US company), and operations were relocated to the US in Kansas City, Kansas.
01/01/2004	closed its offices in the US and Israel, relocated to Singapore.
	Currently, Talshir Medical Technologies Ltd. is an exclusive licensed manufacturer and marketer of NeuroVision(TM) in Israel.

CONTACT INFO

Expand / Collapse All

Main Address: Singapore, Singapore

Address	Marsh & McLennan Centre, 18 Cross St. #07-12
City	Singapore
Country	Singapore
Zip	048423

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Dr. Uri Polat	Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Managing Partner, Concord Ventures
abC Defghij	Board Member	Legal Director , Bio One Capital
abC Defghij	Board Member	Associate Director of Investments, Temasek Holdings
abC Defghij	Board Member	CEO, Neurovision
abC Defghij	Scientific Advisor	Professor of Ophthalmology , Tel Aviv University Sheba Medical Center
abC Defghij	Scientific Advisor	Durrie Vision Clinics,Overland Park, KS, USA
abC Defghij	Scientific Advisor	Chairman & Director of R&D , Vision Sciences Research Corporation, US
abC Defghij	Scientific Advisor	Holladay LASIK Institute, Bellaire, TX, USA
abC Defghij	Scientific Advisor	Head Visual Sciences Group, Australia
abC Defghij	Scientific Advisor	Director, Singapore Eye Research Institute, Dy Director Singapore National Eye Centre
abC Defghij	Advisory Board Member	Managing Partner , Minnesota Eye Consultants
abC Defghij	Advisory Board Member	Managing Director , Schaffer Eye Center
abC Defghij	Advisory Board Member	N\A
abC Defghij	Advisory Board Member	Chairman , Continuing Education for Vision Expo & AOA Clayton Eye Center
abC Defghij	Advisory Board Member	President, Professional Optical Concepts, Draper, UT, USA

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Jan. 01, 2015

Initial Revenues

abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Third Round

Oct. 01, 2007

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Investment Company	abCDe
abC Defghij	Retail	abCDe

Second Round

Oct. 01, 2004

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Investment Company	abCDe

First Round

Apr. 01, 2000

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe	Led the round
abC Defghij	Private Equity Fund	abCDe
abC Defghij	Private Investor	abCDe

Last Updated:	abCDe
IVC Number:	abCDe